PMID- 33939506
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1544-5208 (Electronic)
IS  - 0278-2715 (Linking)
VI  - 40
IP  - 5
DP  - 2021 May
TI  - Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; 
      Impact Of Brand Competition Unclear.
PG  - 772-778
LID - 10.1377/hlthaff.2020.01436 [doi]
AB  - List prices for brand-name drugs have risen steeply, often despite the 
      introduction of competition from other brand-name drugs in the same therapeutic 
      class. List prices, however, do not reflect any rebates that manufacturers 
      provide payers. To understand how net prices (after rebates and other discounts) 
      respond to competition, we compared changes in inflation-adjusted, 
      revenue-weighted mean list and net prices of a one-month supply of three classes 
      of diabetes drugs: glucagon-like peptide 1 (GLP1) agonists, dipeptidyl peptidase 
      4 (DPP4) inhibitors, and sodium glucose cotransporter 2 (SGLT2) inhibitors. These 
      drug classes each had several brand-name products enter the market between 2005 
      and 2017. The annualized change in list price over this period was $75 
      (15 percent) for GLP1 agonists, $22 (8 percent) for DPP4 inhibitors, and $41 
      (11 percent) for SGLT2 inhibitors. In contrast, the annualized change in net 
      price was $38 (10 percent) for GLP1 agonists, -$3 (-2 percent) for DPP4 
      inhibitors, and -$17 (-9 percent) for SGLT2 inhibitors, suggesting a variable 
      impact of brand-name competition on net prices.
FAU - Sarpatwari, Ameet
AU  - Sarpatwari A
AD  - Ameet Sarpatwari (asarpatwari@partners.org) is an assistant professor of medicine 
      and the assistant director of the Program on Regulation, Therapeutics, and Law in 
      the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of 
      Medicine, Brigham and Women's Hospital and Harvard Medical School, in Boston, 
      Massachusetts.
FAU - Tessema, Frazer A
AU  - Tessema FA
AD  - Frazer A. Tessema was a research assistant in the Program on Regulation, 
      Therapeutics, and Law in the Division of Pharmacoepidemiology and 
      Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, when this work was completed. He is an MD candidate at 
      the University of Chicago Pritzker School of Medicine, in Chicago, Illinois.
FAU - Zakarian, Marie
AU  - Zakarian M
AD  - Marie Zakarian is a product manager at Human Care Systems, in Boston, 
      Massachusetts. She was a research assistant in the Program on Regulation, 
      Therapeutics, and Law in the Division of Pharmacoepidemiology and 
      Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, when this work was performed.
FAU - Najafzadeh, Mehdi N
AU  - Najafzadeh MN
AD  - Mehdi N. Najafzadeh is an assistant professor of medicine in the Department of 
      Medicine, Brigham and Women's Hospital and Harvard Medical School.
FAU - Kesselheim, Aaron S
AU  - Kesselheim AS
AD  - Aaron S. Kesselheim is a professor of medicine and the director of the Program on 
      Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and 
      Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Health Aff (Millwood)
JT  - Health affairs (Project Hope)
JID - 8303128
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Diabetes Mellitus
MH  - Drug Costs
MH  - Humans
MH  - Hypoglycemic Agents
MH  - *Pharmaceutical Preparations
EDAT- 2021/05/04 06:00
MHDA- 2021/06/04 06:00
CRDT- 2021/05/03 17:18
PHST- 2021/05/03 17:18 [entrez]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
AID - 10.1377/hlthaff.2020.01436 [doi]
PST - ppublish
SO  - Health Aff (Millwood). 2021 May;40(5):772-778. doi: 10.1377/hlthaff.2020.01436.